Wedge Capital Management L L P NC Buys 1,832 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Wedge Capital Management L L P NC boosted its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 1.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 109,767 shares of the life sciences company’s stock after purchasing an additional 1,832 shares during the period. Wedge Capital Management L L P NC’s holdings in Integra LifeSciences were worth $4,780,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Arizona State Retirement System increased its stake in shares of Integra LifeSciences by 1.3% in the third quarter. Arizona State Retirement System now owns 20,988 shares of the life sciences company’s stock valued at $802,000 after buying an additional 279 shares during the period. Cardinal Capital Management increased its position in Integra LifeSciences by 1.6% in the 4th quarter. Cardinal Capital Management now owns 22,101 shares of the life sciences company’s stock valued at $962,000 after acquiring an additional 347 shares during the period. Inspire Investing LLC raised its stake in shares of Integra LifeSciences by 5.1% during the third quarter. Inspire Investing LLC now owns 8,004 shares of the life sciences company’s stock valued at $306,000 after acquiring an additional 392 shares during the last quarter. Signaturefd LLC lifted its holdings in shares of Integra LifeSciences by 248.5% during the fourth quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock worth $25,000 after purchasing an additional 415 shares during the period. Finally, Covestor Ltd grew its stake in shares of Integra LifeSciences by 82.5% in the third quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock worth $78,000 after purchasing an additional 921 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

Integra LifeSciences stock opened at $29.38 on Thursday. The company has a market capitalization of $2.31 billion, a PE ratio of 35.40, a PEG ratio of 0.88 and a beta of 1.12. Integra LifeSciences Holdings Co. has a 12-month low of $27.85 and a 12-month high of $59.10. The firm’s fifty day moving average is $36.00 and its 200 day moving average is $38.90. The company has a quick ratio of 2.18, a current ratio of 3.45 and a debt-to-equity ratio of 0.94.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.01). The company had revenue of $397.00 million for the quarter, compared to analyst estimates of $399.30 million. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. Integra LifeSciences’s revenue for the quarter was down .3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.94 EPS. As a group, sell-side analysts predict that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IART has been the topic of a number of analyst reports. Citigroup upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price target on the stock in a research report on Wednesday, April 3rd. StockNews.com cut Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Friday, April 5th. JMP Securities lowered their price target on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a report on Thursday, February 29th. Finally, Truist Financial dropped their target price on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a report on Friday, March 1st. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Integra LifeSciences has an average rating of “Hold” and a consensus price target of $44.89.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.